CJC/IPA Protocol and Dianabol Interaction: Monitor | Peptide Database

Join others researching Oxiracetam — share findings, ask questions, and learn from real experiences Oxiracetam (ISF-2522) is a synthetic nootropic compound belonging to the racetam family, first developed in the 1970s by ICF, an Italian pharmaceutical company. It is a hydroxylated derivative of piracetam and is approved as a prescription medication in Italy and several other European and Asian countries for the treatment of cognitive decline associated with dementia and organic brain syndromes. Among the racetams, oxiracetam is widely regarded as the most effective for logical reasoning, mathematical thinking, and technical work -- a reputation that distinguishes it from piracetam, which users more commonly associate with verbal fluency and creative thinking. Oxiracetam is well absorbed orally with high bioavailability, is not significantly metabolized by the liver, and is excreted largely unchanged by the kidneys, giving it a clean pharmacokinetic profile with minimal drug-drug interaction potential. Oxiracetam enhances cognitive function primarily through positive allosteric modulation of AMPA-type glutamate receptors, increasing the excitatory postsynaptic response to glutamate and facilitating long-term potentiation (LTP) in hippocampal and cortical circuits. This AMPA modulation is thought to underlie its effects on memory encoding and retrieval. Additionally, oxiracetam stimulates cholinergic neurotransmission by increasing the release of acetylcholine in the hippocampus and cortex, which contributes to improvements in attention, working memory, and the speed of information processing. Unlike some stimulant nootropics, oxiracetam does not act on dopaminergic or serotonergic systems, which accounts for its low abuse potential and absence of mood-altering side effects. Oxiracetam also increases phospholipid metabolism in the brain, specifically the turnover of phosphatidylcholine and phosphatidylethanolamine, which may support membrane integrity and synaptic function. The compound increases D-aspartate release in the hippocampus, providing an additional pathway for NMDA receptor activation and synaptic plasticity. Its selectivity for logical and analytical cognition, as reported by users, may relate to preferential enhancement of cortical circuits involved in sequential reasoning and working memory manipulation, though this distinction has not been rigorously dissected in controlled studies.

FDA-approved for the treatment of major depressive disorder, though it is rarely used as a primary antidepressant today due to the availability of SSRIs and SNRIs with more favorable side effect profiles for daytime use. Antidepressant doses range from 150-400 mg/day, significantly higher than the doses used for sleep. The most common clinical use of trazodone today. Low doses (25-100 mg) at bedtime reduce sleep onset latency, improve sleep continuity, and enhance slow-wave sleep. Multiple studies support its efficacy, and it is the most frequently prescribed off-label medication for insomnia in the United States. Particularly valued because it avoids the dependence and rebound insomnia associated with benzodiazepines and Z-drugs. Extremely popular in the bodybuilding and PED community for managing sleep disruption caused by anabolic steroids, particularly trenbolone (19-nortestosterone derivatives). Trenbolone is notorious for causing severe insomnia and night sweats, and trazodone at 50-100 mg is one of the most reliable and accessible solutions. Its non-addictive profile makes it suitable for use throughout entire steroid cycles. Useful for patients whose insomnia is driven by anxiety or racing thoughts at bedtime. The 5-HT2A antagonism and mild anxiolytic properties help quiet mental activity without the cognitive impairment of benzodiazepines. Often added to an existing SSRI or SNRI regimen specifically to address insomnia. Low-dose trazodone at bedtime can complement a daytime antidepressant without significant drug interaction concerns at typical doses.